 Rabbit antithymicite globulins, RATGs, are currently used as an induction therapy to prevent acute rejection, AR, following kidney transplantation. However, their use has been limited due to potential side effects such as opportunistic infections and de novo post-transplant cancer. Recently, researchers have found that takrolimus plus everolimus, rather than takrolimus plus mycophenolic acid, can be used as maintenance immunosuppressants while reducing the risk of CMV infection. Additionally, research suggests that RATGs can be used in combination with mammalian target of rapamycin, ENTER, inhibitors to further reduce the risk of AR. This article was authored by Paolo Malvatsi, Thomas Jove, and Lionel Rosting.